Table 1.
Parameters’ value in the partitioned survival model.
| Base Value ($) | DSA range ($) | PSA Distribution | Reference | |
|---|---|---|---|---|
| Price of pembrolizumab | 2,768.50/100mg | 2,076.45-3,460.70 | lognormal | (11) |
| Price of carboplatin | 0.17/mg | 0.13-0.22 | lognormal | (11) |
| Price of pemetrexed | 330.96/100mg | 248.30-413.78 | lognormal | (11) |
| Price of nivolumab | 1,430.76/100mg | 1,073.07-1,788.45 | lognormal | (12) |
| Price of docetaxel | 200.86/200mg | 150.65-251.08 | lognormal | (13) |
| Cost of medical service of pembrolizumab therapy per cycle | 8.69 | 6.52-10.86 | lognormal | (11) |
| Cost of medical service of chemotherapy per cycle | 48.71 | 36.53-60.89 | lognormal | (11) |
| Cost of imaging examination and laboratory test per cycle | 62.02 | 46.52-77.53 | lognormal | (4, 11) |
| Utility of PFS | 0.804 | 0.683-0.925 | beta | (14) |
| Utility of PD | 0.321 | 0.273-0.369 | beta | (14) |
| Utility of death | 0 | – | – | – |
| Discount rate | 5% | 0-8% | – | (10) |
DSA, deterministic sensitivity analyses; PSA, probabilistic sensitivity analyses.